Señales en vivo de ALBT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 may 2024 @ 16:00):

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China...

Stats
Volumen de hoy	24 323.00
Volumen promedio	190 072
Capitalización de mercado	3.42M
EPS	$0 ( 2024-04-02 )
Próxima fecha de ganancias	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.190
ATR14	$0.00900 (2.92%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2021-05-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2022-05-01	Tauzin W J	Buy	8 000	Stock Option right to buy)
2022-11-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2022-01-01	Tauzin W J	Buy	4 000	Stock Option (right to buy)

INSIDER POWER
99.83
Last 100 transactions
Buy: 44 704 561 \| Sell: 8 187 803

Volumen Correlación

Largo: -0.27 (neutral)

Corto: 0.48 (neutral)

Signal:(56.49) Neutral

Avalon GloboCare Corp. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Avalon GloboCare Corp. Correlación - Moneda/Commodity

-0.49
( neutral )

-0.48
( neutral )

0.00
( neutral )

-0.09
( neutral )

Avalon GloboCare Corp. Finanzas

Annual	2023
Ingresos:	$1.26M
Beneficio Bruto:	$202 789 (16.15 %)
EPS:	$-1.590

FY	2023
Ingresos:	$1.26M
Beneficio Bruto:	$202 789 (16.15 %)
EPS:	$-1.590

FY	2022
Ingresos:	$1.20M
Beneficio Bruto:	$272 728 (22.69 %)
EPS:	$-1.360

FY	2021
Ingresos:	$1.39M
Beneficio Bruto:	$414 518 (29.80 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Avalon GloboCare Corp. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Avalon GloboCare Corp.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.